GLP-1 medications, initially developed for – and approved to treat – type 2 diabetes, are now at the center of a growing debate within pharmacy benefits. While some of these drugs have proven effective for weight loss, the rising impact of their high costs is creating significant financial challenges for employers.
With prescription drug spending up nearly 10% in 2023, this article examines the tough decisions employers face when balancing costs and ensuring proper access to medications.
In a recent BenefitsPRO article, RxBenefits explores how the surge in GLP-1 prescriptions – especially for off-label use – has impacted pharmacy spending and what employers can do to manage these costs.
